| 1 |
35532631 | The Influence of ADORA2A on Levodopa-Induced Dyskinesia. | 2022 Mar-Apr |
2 |
| 2 |
33831661 | Effect of dopaminergic medication on adenosine 2A receptor availability in patients with Parkinson's disease. | 2021 May |
1 |
| 3 |
34004240 | Caffeine, a natural methylxanthine nutraceutical, exerts dopaminergic neuroprotection. | 2021 Sep |
1 |
| 4 |
34767786 | Analysis of L-DOPA and droxidopa binding to human β2-adrenergic receptor. | 2021 Dec 21 |
1 |
| 5 |
32236790 | The belated US FDA approval of the adenosine A2A receptor antagonist istradefylline for treatment of Parkinson's disease. | 2020 Jun |
1 |
| 6 |
33349576 | Can adenosine A2A receptor antagonists modify motor behavior and dyskinesia in experimental models of Parkinson's disease? | 2020 Nov |
1 |
| 7 |
30253174 | Occupancy of adenosine A2A receptors by istradefylline in patients with Parkinson's disease using 11C-preladenant PET. | 2018 Dec |
1 |
| 8 |
29375464 | A Meta-Analysis of Adenosine A2A Receptor Antagonists on Levodopa-Induced Dyskinesia In Vivo. | 2017 |
1 |
| 9 |
25499739 | The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets. | 2015 Jan 15 |
1 |
| 10 |
25872644 | Is there a role for ADORA2A polymorphisms in levodopa-induced dyskinesia in Parkinson's disease patients? | 2015 |
2 |
| 11 |
26415982 | The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets. | 2015 Nov 5 |
1 |
| 12 |
23339054 | Caffeine consumption and risk of dyskinesia in CALM-PD. | 2013 Mar |
1 |
| 13 |
21606452 | Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. | 2011 May 24 |
1 |
| 14 |
18438720 | Adenosine A(2A) receptors in Parkinson's disease treatment. | 2008 Dec |
1 |
| 15 |
12913187 | Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. | 2003 Aug 12 |
1 |
| 16 |
11852293 | A double-blind crossover, placebo-controlled study of the adenosine A2A antagonist theophylline in Parkinson's disease. | 2002 Jan-Feb |
1 |